Allspring Global Investments Holdings LLC Sells 8,672 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Allspring Global Investments Holdings LLC decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 152,738 shares of the biotechnology company's stock after selling 8,672 shares during the period. Allspring Global Investments Holdings LLC owned 0.25% of Ascendis Pharma A/S worth $21,077,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Westfield Capital Management Co. LP boosted its holdings in Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock valued at $766,523,000 after acquiring an additional 170,942 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after buying an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock worth $278,760,000 after buying an additional 155,971 shares during the last quarter. Groupama Asset Managment bought a new position in Ascendis Pharma A/S during the third quarter worth about $60,000. Finally, ARS Investment Partners LLC boosted its holdings in Ascendis Pharma A/S by 0.9% during the fourth quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company's stock worth $36,549,000 after buying an additional 2,369 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock traded down $1.08 during midday trading on Wednesday, reaching $155.11. The stock had a trading volume of 682,827 shares, compared to its average volume of 513,308. The firm's fifty day simple moving average is $133.20 and its 200-day simple moving average is $132.57. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The stock has a market capitalization of $9.41 billion, a P/E ratio of -21.85 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ASND shares. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Oppenheimer reduced their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. The Goldman Sachs Group raised their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, Wedbush reaffirmed an "outperform" rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $197.36.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.